ERC Advanced Grant · 2024
Foxp3+ regulatory T cells (Tregs) are highly potent immunosuppressive cells. Most of our understanding of Tregs is based on the population present in lymphoid tissues, however to harness their anti-inflammatory power in the clinic we need to understand the tissue-resident population. Converting generic Tregs into expanded proto-tissue Tregs, capable of entering inflamed tissues, adapting to local conditions, and driving an anti-inflammatory pro-rejuvenation process would transform cell therapy. However to be able to encode a tissue-resident function into Tregs, we first need to decode the cellular induction signals that allow a Treg to become a tissue Treg, and decode the molecular…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.